Kevin Shannon, MD
Hematology & Oncology · Findlay, OHNPI 1881697894
Payments from drug & device makers
Across 251 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$657
- AstraZeneca$500
- Eisai Inc.$370
- Merck$357
- Pfizer$337
- AbbVie$331
- plus $3K from 33 others
What the payments were for
- Food & beverage$4,72088%
- Education$62712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $657 |
| AstraZeneca | 24 | $500 |
| Eisai Inc. | 18 | $370 |
| Merck | 21 | $357 |
| Pfizer | 22 | $337 |
| AbbVie | 11 | $331 |
| E.r. Squibb & Sons, L.L.C. | 17 | $317 |
| Novartis | 15 | $303 |
| Gilead | 10 | $215 |
| Incyte Corporation | 9 | $207 |
| Bristol Myers Squibb | 8 | $202 |
| Genentech USA, Inc. | 4 | $156 |
| Astellas Pharma US Inc | 6 | $132 |
| Acrotech Biopharma Inc. | 6 | $119 |
| Seagen Inc. | 2 | $116 |
| Array Biopharma Inc | 6 | $87 |
| Amgen | 5 | $87 |
| Tempus AI, Inc | 4 | $78 |
| EMD Serono, Inc. | 3 | $78 |
| Jazz Pharmaceuticals Inc. | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| GSK | 3 | $63 |
| Exelixis Inc. | 3 | $54 |
| Rigel Pharmaceuticals, Inc. | 3 | $52 |
| Foundation Medicine, Inc. | 3 | $50 |
| Myriad Genetic Laboratories, Inc. | 1 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Karyopharm Therapeutics Inc. | 2 | $31 |
| Bayer | 2 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| Taiho Oncology, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Tesaro, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$110
How this compares
$5,346 in reported general payments places this provider in the 45th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 28 | $629,122 |
| ImbruvicaIbrutinib | 34 | $501,875 |
| TagrissoOsimertinib Mesylate | 26 | $444,943 |
| Lenalidomide | 28 | $419,978 |
| LenvimaLenvatinib Mesylate | 15 | $356,178 |
| XtandiEnzalutamide | 21 | $275,203 |
| KisqaliRibociclib Succinate | 13 | $220,903 |
| CalquenceAcalabrutinib Maleate | 19 | $165,833 |
| VenclextaVenetoclax | 23 | $69,444 |
| Abiraterone Acetate | 21 | $53,531 |
| EliquisApixaban | 25 | $27,330 |
| Fentanyl | 15 | $2,974 |
| Anastrozole | 89 | $1,714 |
| Exemestane | 13 | $858 |
| Hydroxyurea | 32 | $725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $317 | $629,12228 claims |
| AstraZenecaTagrisso, Calquence | $500 | $610,77545 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $28 | $501,87534 claims |
| Eisai Inc.Lenvima | $370 | $356,17815 claims |
| Astellas Pharma US IncXtandi | $132 | $275,20321 claims |
| NovartisKisqali | $303 | $220,90313 claims |
| AbbVieVenclexta | $331 | $69,44423 claims |
| PfizerEliquis | $337 | $27,33025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Findlay
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.